/
Oncology
Neuroblastoma
90
Pipeline Programs↗
88
Active Trials↗
43
Companies Involved↗
Neuroblastoma is a moderately active landscape with 90 programs across 43 companies. The most active players are Princess Maxima Center for Pediatric Oncology, Ascentage Pharma Group Inc., Eli Lilly. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 123
Phase 237
Phase 322
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
58 of 81 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 81 classified programs, each share of the total. Modality classified for 98% of 90 pipeline programs.
Analysis
Trial Status
284
clinical trials
Completed120 · 42%
Recruiting48 · 17%
Active, not recruiting31 · 11%
Unknown status29 · 10%
Terminated28 · 10%
Withdrawn9 · 3%
Other19 · 7%
Clinical Trials
Trial Activity
284 trials
Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Recruiting·—·Phase 2·NCT06540963·98 enrolled
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Recruiting·—·Phase 2·NCT05489887·93 enrolled
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)